SGLT2抑制劑之”心”發現

SGLT2 inhibitors : A New Era in the Treatment of Heart Failure

10.6647/CN.202303_30(1).0005

徐雅玫(Ya-Mei, Hsu)

第2型鈉－葡萄糖共同轉運蛋白抑制劑 ； 心衰竭 ； dapagliflozin ； empagliflozin ； Sodium glucose cotransporter 2 inhibitors ； SGLT2 inhibitors ； heart failure ； dapagliflozin ； empagliflozin

彰化護理

30卷1期（2023 / 03 / 01）

20 - 25

繁體中文;英文

隨著人口老化，臺灣心衰竭的病人逐年增加。心衰竭藥物治療變更為四大類，指引導向藥物治療在心衰竭合併射出分率減少族群新增加了SGLT2抑制劑。SGLT2抑制劑已被證明對多種疾病具有心臟和腎臟保護作用，包括第二型糖尿病、慢性腎病和心衰竭。在心衰竭病人族群，SGLT2抑制劑的臨床益處首先在心衰竭合併射出分率減少的病人中得到證實，現在被強烈推薦作為糖尿病合併心衰竭的首選藥物。

Heart failure is a growing epidemic, especially in Taiwan because of the aging population. Guideline-directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF) now includes 4 medication classes that include SGLT2 inhibitors. SGLT2 inhibitors have been shown to have salutary cardioprotective and renoprotective effects in various diseases including type 2 diabetes, chronic kidney disease, and heart failure. In patients with heart failure, the clinical benefits of SGLT2 inhibitors were first established in those with reduced ejection fraction and are now strongly recommended as first-line treatment in patients with diabetes mellitus and heart failure.

1. McMurray, J. J.,Solomon, S. D.,Inzucchi, S. E.,Køber, L.,Kosiborod, M. N.,Martinez, F. A.,Langkilde, A. M.(2019).Dapagliflozin in patients with heart failure and reduced ejection fraction.New England Journal of Medicine,381(21),1995-2008.
2. Packer, M.,Anker, S. D.,Butler, J.,Filippatos, G.,Pocock, S. J.,Carson, P.,Zannad, F.(2020).Cardiovascular and renal outcomes with empagliflozin in heart failure.New England Journal of Medicine,383(15),1413-1424.
3. Vaduganathan, M.,Docherty, K. F.,Claggett, B. L.,Jhund, P. S.,de Boer, R. A.,Hernandez, A. F.,Solomon, S. D.(2022).SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials.The Lancet,400(10354),757-767.
4. Zinman, B.,Wanner, C.,Lachin, J. M.,Fitchett, D.,Bluhmki, E.,Hantel, S.,Inzucchi, S. E.(2015).Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.New england journal of medicine,373(22),2117-2128.
5. 中華民國心臟衰竭照護學會(2019，11月09日)．心衰竭護理指導手冊。取自 https://www.heartfailure.tw/health_edu/nursing/96
6. 衛生福利部食品藥物管理署(2021，8月20日)．Dapagliflozin(Forxiga®) 福適佳仿單。取自https://info.fda.gov.tw/MLMS/H0001D31.aspx?LicId=52026476
7. 衛生福利部食品藥物管理署(2021，11月25日)．Egliflozin(Steglatro®) 穩適妥仿單。取自https://info.fda.gov.tw/MLMS/H0001D31.aspx?LicId=52027455
8. 衛生福利部食品藥物管理署 (2022，11 月11 日) ．Empagliflozin(Jardiance®) 恩排糖仿單。取自https://mcp.fda.gov.tw/im_detail_1/%E8%A1%9B%E9%83%A8%E8%97%A5%E8%BC%B8%E5%AD%97%E7%AC%AC026406%E8%99%9F
9. 衛生福利部食品藥物管理署(2022，11月23日)．Canagliflozin(Canaglu®) 可拿糖說明書(第五版)。取自 https://info.fda.gov.tw/MLMS/H0001D31.aspx?LicId=52026950